The Zacks Analyst Blog Highlights: Innovative Industrial Properties and GW Pharmaceuticals
For Immediate Release
Chicago, IL - June 8, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Innovative Industrial Properties, Inc. IIPR and GW Pharmaceuticals PLC GWPH .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday's Analyst Blog:
Canada to Legalize Marijuana: Will Cannabis Industry Bloom?
The marijuana industry witnessed significant profits in the last few years after the recent trend of legalization supported the industry. In the United States, nine states have legalized the recreational use of marijuana. Moreover, 29 U.S. states have legalized medical marijuana, though at the federal level, marijuana use is still banned.
The country's northern neighbor, Canada, had legalized medical use of marijuana way back in 2001. Additionally, Canada has now geared up to legalize recreational marijuana this summer, which in turn has brought attention back to the cannabis industry. Moreover, several marijuana giants are now eyeing foreign markets like Africa to improve growth opportunities, which is also good news.
Canada: First G7 Nation to Legalize Marijuana
More than 17 years ago, Canada legalized the use of marijuana for medical purposes. Moreover, the country recently introduced the Cannabis Act and is all set to legalize the recreational use of marijuana by the end of next month. Today, Canadian Prime Minister Justin Trudeau and Senate of Canada will be voting in favor of the C-45 bill that will help in legalizing marijuana use.
According to several projections, the Canadian cannabis industry is expected to produce 800,000 kilograms of marijuana per year after the legalization. Further, Canadians are estimated to incur a total expenditure of $7.17 billion on marijuana products in 2019, with overall consumption increasing by 35%, per a Deloitte report.
In fact, legal recreational marijuana sales are expected to be around $4.34 billion next year. Moreover, illegal sales and purchase of marijuana will be reduced significantly after the availability of legal cannabis. Along with, Canada, another profitable marijuana market is the United States.
Marijuana Sales in U.S. to Jump 28% by 2021
After eight states, California is the latest to legalize the usage of marijuana for recreational purpose. Moreover, Washington D.C. (District of Columbia) has also legalized recreational marijuana usage. However, earlier this year, this optimism hit a roadblock when Attorney General Jeff Sessions said that it is necessary to "return to the rule of law" to repeal the Obama-era marijuana-friendly state laws.
However, all is not as lost as legal marijuana sales in the United States increased significantly in 2017. According to a report by ArcView Market Research and BDS Analytics, sales of legal marijuana in North America increased 33% in 2017. Moreover, in the next four years, i.e. 2018-2021, legal marijuana sales are estimated to surge 28%, touching a new high of $25 billion. If the data came true, it will be significantly higher than 2017's performance.
Africa Holds Prospects for Marijuana
Canadian marijuana giants are clearly moving beyond their known terrain and now looking for new markets like Africa. One such major medical cannabis seller, Aphria Inc. is looking for more business in Africa. This is mainly because, in the African continent, marijuana of 10,000 tons or higher is being produced each year, per a UN survey. Additionally, African countries like Lesotho and then Zimbabwe have legalized the production of marijuana for medical and scientific purpose.
Given this scenario, companies related to the marijuana industry like Terra Tech Corp., GrowGeneration Corp., Innovative Industrial Properties, Inc. and GW Pharmaceuticals PLC are expected to gain. Both Innovative Industrial Properties and GW Pharmaceuticals have a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank stocks here .
Undoubtedly, the marijuana industry is booming at present, following the legalization of both medical and now recreational cannabis in Canada. Moreover, strong growth prospect in its two major markets, Canada and the United States is also a positive. Also, recent development in the African continent is expected to boost the marijuana industry further.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.